Literature DB >> 25201958

Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses.

Christian Königer1, Ida Wingert2, Moritz Marsmann2, Christine Rösler2, Jürgen Beck3, Michael Nassal3.   

Abstract

Hepatitis B virus (HBV), the causative agent of chronic hepatitis B and prototypic hepadnavirus, is a small DNA virus that replicates by protein-primed reverse transcription. The product is a 3-kb relaxed circular DNA (RC-DNA) in which one strand is linked to the viral polymerase (P protein) through a tyrosyl-DNA phosphodiester bond. Upon infection, the incoming RC-DNA is converted into covalently closed circular (ccc) DNA, which serves as a viral persistence reservoir that is refractory to current anti-HBV treatments. The mechanism of cccDNA formation is unknown, but the release of P protein is one mandatory step. Structural similarities between RC-DNA and cellular topoisomerase-DNA adducts and their known repair by tyrosyl-DNA-phosphodiesterase (TDP) 1 or TDP2 suggested that HBV may usurp these enzymes for its own purpose. Here we demonstrate that human and chicken TDP2, but only the yeast ortholog of TDP1, can specifically cleave the Tyr-DNA bond in virus-adapted model substrates and release P protein from authentic HBV and duck HBV (DHBV) RC-DNA in vitro, without prior proteolysis of the large P proteins. Consistent with TPD2's having a physiological role in cccDNA formation, RNAi-mediated TDP2 depletion in human cells significantly slowed the conversion of RC-DNA to cccDNA. Ectopic TDP2 expression in the same cells restored faster conversion kinetics. These data strongly suggest that TDP2 is a first, although likely not the only, host DNA-repair factor involved in HBV cccDNA biogenesis. In addition to establishing a functional link between hepadnaviruses and DNA repair, our results open new prospects for directly targeting HBV persistence.

Entities:  

Keywords:  TDP substrate specificity; hepatitis B virus persistence; virus–DNA repair interface

Mesh:

Substances:

Year:  2014        PMID: 25201958      PMCID: PMC4209993          DOI: 10.1073/pnas.1409986111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  64 in total

1.  Uses and misuses of progress curve analysis in enzyme kinetics.

Authors:  Natalia Nikolova; Kiril Tenekedjiev; Krasimir Kolev
Journal:  Cent Eur J Biol       Date:  2008-12-01

2.  A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases.

Authors:  S W Yang; A B Burgin; B N Huizenga; C A Robertson; K C Yao; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 3.  The cutting edges in DNA repair, licensing, and fidelity: DNA and RNA repair nucleases sculpt DNA to measure twice, cut once.

Authors:  Susan E Tsutakawa; Julien Lafrance-Vanasse; John A Tainer
Journal:  DNA Repair (Amst)       Date:  2014-04-19

4.  Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase.

Authors:  Judit Vörös; Annika Urbanek; Gilles Jean Philippe Rautureau; Maggie O'Connor; Henry C Fisher; Alison E Ashcroft; Neil Ferguson
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

Review 5.  Pleiotropic functions of EAPII/TTRAP/TDP2: cancer development, chemoresistance and beyond.

Authors:  Chunyang Li; Shi-Yong Sun; Fadlo R Khuri; Runzhao Li
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

6.  Efficient Hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein.

Authors:  Jürgen Beck; Michael Nassal
Journal:  J Biol Chem       Date:  2003-07-08       Impact factor: 5.157

Review 7.  Hepatitis B virus resistance to nucleos(t)ide analogues.

Authors:  Fabien Zoulim; Stephen Locarnini
Journal:  Gastroenterology       Date:  2009-09-06       Impact factor: 22.682

8.  Conditional replication of duck hepatitis B virus in hepatoma cells.

Authors:  Ju-Tao Guo; Melissa Pryce; Xingtai Wang; M Inmaculada Barrasa; Jianming Hu; Christoph Seeger
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1.

Authors:  Zhihong Zeng; Abhishek Sharma; Limei Ju; Junko Murai; Lieve Umans; Liesbeth Vermeire; Yves Pommier; Shunichi Takeda; Danny Huylebroeck; Keith W Caldecott; Sherif F El-Khamisy
Journal:  Nucleic Acids Res       Date:  2012-06-26       Impact factor: 16.971

10.  TDP2/TTRAP is the major 5'-tyrosyl DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage.

Authors:  Zhihong Zeng; Felipe Cortés-Ledesma; Sherif F El Khamisy; Keith W Caldecott
Journal:  J Biol Chem       Date:  2010-10-28       Impact factor: 5.157

View more
  95 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

2.  Identification of an Intermediate in Hepatitis B Virus Covalently Closed Circular (CCC) DNA Formation and Sensitive and Selective CCC DNA Detection.

Authors:  Jun Luo; Xiuji Cui; Lu Gao; Jianming Hu
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

Review 3.  Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.

Authors:  Ju-Tao Guo; Haitao Guo
Journal:  Antiviral Res       Date:  2015-08-10       Impact factor: 5.970

Review 4.  Antiviral therapies and prospects for a cure of chronic hepatitis B.

Authors:  Fabien Zoulim; David Durantel
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 5.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

6.  Potential newer therapeutic targets for hepatitis B virus drug development.

Authors: 
Journal:  J Clin Exp Hepatol       Date:  2014-11-27

Review 7.  Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.

Authors:  Bidisha Mitra; Roshan J Thapa; Haitao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2018-08-24       Impact factor: 5.970

8.  Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.

Authors:  Evgeny Kiselev; Azhar Ravji; Jayakanth Kankanala; Jiashu Xie; Zhengqiang Wang; Yves Pommier
Journal:  DNA Repair (Amst)       Date:  2019-11-06

Review 9.  Revisiting Hepatitis B Virus: Challenges of Curative Therapies.

Authors:  Jianming Hu; Ulrike Protzer; Aleem Siddiqui
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 10.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.